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To assess the feasibility and acceptability of offering self-sampling for HPV testing to cervical screening non-attenders when they consult primary care for any reason.
Setting
A pilot implementation study in six GP practices in London, UK.
Methods
GP practices offered self-sampling kits during consultation to women aged 25-64 who were at least 6 months overdue cervical screening (i.e. no cytology test recorded in the past 3.5 (if aged 25-49) or 5.5 years (if aged 50-64)). Eligible women were identified using an automated real-time search (during consultation) of the GP electronic medical record system. Women collected samples either in clinic or at home (dry flocked swabs analysed using Roche Cobas®4800).
Results
3,131 of approximately 5,000 eligible women consulted between Jan-Dec 2014 (mean recruitment period 9.5 months). Of these, 21% (652) were offered kits, 14% (443) accepted and 9% (292) returned a self-sample. 
The proportion of eligible women offered kits varied considerably between practices (11%-36%). Sample return rates increased with kit offered rates (r=0.8, p=0.04).
82% (32) of 39 HPV positive women attended follow-up including two with invasive cancers (stage 2A1 and 1A1).
Conclusions
Offering self-sampling to cervical screening non-attenders opportunistically in primary care is feasible. Return rates could be even higher if more women were offered kits. A large trial is needed to identify how self-sampling is best integrated into the national screening programme and to identify determinants of uptake. 
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Conventional cervical screening relies on clinician-collected samples but the introduction of human papillomavirus (HPV) testing has opened up the possibility of self-collected samples. Self-sampling (SS) can overcome many of the barriers to cytological screening; both emotional (e.g. embarrassment, fear of pain) and practical (e.g. difficulty making appointments). Women can take a sample themselves in private, at a time and place of their choosing without needing to be examined, thereby saving both clinician time and clinic costs. Furthermore, meta-analysis has shown that HPV testing on self-collected samples is at least as sensitive as good quality cytology.(1) However, self-sampling is slightly less sensitive than HPV testing of clinician-collected samples (with similar specificity). ADDIN EN.CITE (2) The Dutch screening programme has already announced that self-sampling will be offered to cervical screening nonattendees from 2016, and it is anticipated that several other countries will soon follow suit.
Numerous non-UK studies ADDIN EN.CITE (3-9) have shown that self-sampling can increase screening uptake in nonattenders (~30-40% response), and that around 80% of women who test HPV positive attend follow up investigations.  Sending kits directly to women has been the most commonly assessed approach and the only one (to date) that has been shown to increase uptake in randomised studies. An obvious disadvantage is the high number of wasted kits and the associated costs.  Opt-in strategies do not appear to work well. ADDIN EN.CITE (7, 10) 
The picture in the UK is less clear; two studies ADDIN EN.CITE (11, 12) posted self-sampling kits to cervical screening nonattenders but only 6%-8% of women returned a self-sample (i.e. >92% kit attrition and the lowest response rates of all self-sampling studies to date).  A series of studies in Dumfries and Galloway found that 5-20% of screening nonattenders returned a self-sample when asked to request SS kits or SS kits were sent directly to women.(13) Further evidence is needed before self-sampling can be recommended for integration into UK screening programmes.
One approach that has not been studied is the more targeted approach of offering self-sampling to screening nonattenders when they consult primary care for any reason. Key advantages include fewer wasted kits (because they are handed directly to women) and an in-person contact with a population who are difficult to engage. ADDIN EN.CITE (14, 15) An audit of electronic primary care records found that of women >6 months overdue cervical screening, 32% consulted over 3 months and 60% over 1 year.(16) These figures suggest that a large proportion of relevant women could be approached in this way. Here we report on a pilot study to assess the acceptability and feasibility of offering self-sampling for HPV testing to cervical screening nonattenders opportunistically in primary care. 
Methods
We recruited six general practices in London to take part including four from East London two from South London. Practices were required to have EMIS web (Egton Medical Information Systems Ltd, 2010) electronic patient record system. We also targeted practices with low cervical screening coverage (below 75% of eligible women screened in the previous 5 years). Eligible women were aged 25-64 years who were overdue cervical screening by at least 6 months. 
In England, cervical screening is offered to women aged 25-49 every 3 years and to women aged 50-64 every 5 years. An automatic search was set up in EMIS web to flag women (in real time) who did not have a cytology entry recorded in EMIS in the last 42 months for women aged 28-49 and 66 months for women aged 50-64).  The lower age limit for the search was set to 28 instead of 25 in order to focus on women who were ‘true’ screening non-attenders and not still deciding to respond to their first invitation. An alert message appeared on screen for eligible women when their record was opened. General practitioners (GPs), nurses and health care assistants were asked to offer flagged women a self-sampling kit during any (non-cervical screening) consultation and to record reasons for declining kits. Kits contained a flocked swab in a self-sealing tube (FLOQSwabs™, Copan Italia, Brescia, Italy), a plastic specimen bag, an instruction leaflet for self-sampling (written and pictorial), an HPV information leaflet, a study information leaflet and a prepaid envelope for returning samples. Women were able to choose between taking their sample in clinic (behind a curtain or in the lavatories) or at home. Women who collected samples in clinic handed them to a member of staff for sending to the relevant testing laboratory. Women who collected samples at home posted them to the laboratory using the prepaid envelope. Samples were transported dry and were analysed at one of two laboratories (Barts Health NHS Trust cellular pathology and Preventx Limited commercial laboratory) depending on the GP practice catchment area. Both laboratories used Cobas® 4800HPV Test (Roche Diagnostics GmBH) for HPV testing.
Women who tested HPV positive were advised in their results letter to book a cytology test in primary care. Those who had not had cytology within six months of testing HPV positive were invited to a study smear/colposcopy clinic where they were offered cytology with or without colposcopy. 
Women who tested HPV negative were exited from the study. Given that self-samples are not currently included in the national cervical screening programme, only cytology tests were able to change the women’s screening status and contribute towards the GP practice coverage statistics (which is linked to GP payments and used as an indicator of GP practice quality). This meant that some women who tested HPV negative on a self-sample also had a subsequent cytology test, either of their own accord or following active encouragement from their GP practice.
Feedback from GP practices was obtained throughout the study on an informal and ad-hoc basis (e.g. by attending clinical meetings, during monitoring visits or via email).
Statistical Analysis
The aim of the study was to assess the feasibility and acceptability of opportunistic offering self-sampling to cervical screening non-attenders in GP primary care as measured by the proportion of eligible women who are offered kits, who accept kits and who return a self-sample.
The exact number of cervical screening non-attenders over the study period was not known because the dates that women registered and leave (unregister) GP practices are not reliably recorded in EMIS. We were therefore unable to determine whether women who left during the study were overdue screening before leaving.  Instead we estimated the total number of eligible women as the number of women who were >6 months overdue and were still registered at the end of the study plus the number >6 months overdue who consulted but left during the study. Response rates were calculated using the proportion of eligible women (overdue cervical cytology by at least 6 months) who consulted that accepted a self-sampling kit (ie responders) and that returned a self-sampling kit. 
Cervical screening status was classified using the time from last recorded cytology before invitation as 1) ‘late’ – women who were overdue by 6-24 months, 2) ‘very late’ - women who were overdue by at least 24 months and 3) ‘never’ - women with no cytology tests recorded.
Descriptive statistics were used to compare demographic and cervical screening status between responders and non-responders. 
For women who tested HPV positive we calculated the proportion who had a follow up investigation within 6 months.
The χ2 test was used to test for differences in proportions between groups. Pearson’s correlation coefficient was used to measure the strength of association between the proportion of women offered kits and the proportion who returned a self-sample at each practice.
All analyses were performed using Stata version 13 (College Station, TX: StataCorp LP). A p value of less than 0.05 was considered statistically significant. All statistical tests were two-sided.
Results
Between January and December 2014, 3,131 of approximately 5,000 eligible women consulted GP primary care. The mean recruitment period was 9.5 months (range 7.8 months to 10.7 months).  Of the 3,131 women, 20.8% (652) were offered a self-sampling kit, 14.1% (443) accepted and 9.3% (292) returned a self-sample (i.e. 45% of those offered returned a sample) – see Figure 1. This is equivalent to an annual rate of screening via self-sampling of about 7% of non-attenders, but varied from 4% to 27% between practices.
Table 1 shows the characteristics of participating GP practices and of eligible women who returned a self-sample. The estimated number of women aged 25-64 years who were >6 months overdue cervical screening ranged from 549 to 946 between practices.  Most women (79.1%) who returned a sample were aged 25-49 and almost half were of White ethnicity (47.9%).  Seventy-four per cent (217/292) were at least two years overdue cervical screening (including 47% who had no cytology recorded implying they had never been screened). Of the 292 self-samples returned, 91% (267) returned their sample within one month.  Three samples were taken by a clinician (using the swab from the kit); one because a pelvic vaginal examination was carried out at the time of consultation and two because the women reported being unable to take the self-sample themselves.  Six samples were not interpretable due to insufficient DNA (these women were sent a new kit). Of the readable samples, 13.6% (39) were HPV positive (4.2% HPV16 and 0.4% HPV18) and the remaining were HPV negative.  Four of the women with insufficient DNA provided a second self-sample, all tested HPV negative.  An additional 40 self-samples were returned by women who were not eligible (not >6m overdue when invited (n=28), smear taken same day as invited (n=11), not aged 25-64 at invitation (n=1)).
A high proportion (84.6%, 33/39) of women who tested HPV positive attended follow-up investigations (four at the study colposcopy/smear clinic). Just over half (22/39) attended within 3 months (median of 1.3 months from HPV positive result to follow-up (interquartile range 0.8 - 4.1 months). The majority (72.7%) had negative cytology (see Table 2). One woman was found to have stage 2A1 invasive cervical cancer, one microinvasive 1A1 and one woman had CIN1. 
The most common reason (30.6%) women provided for declining a self-sampling kit was that they preferred or intended to book a smear. However, only 52% (33/64) of those who said this had had a smear within the subsequent 6 months. 
Only 11% (27/247) of women who tested HPV negative had a smear within 6 months of returning a self-sample.
There was substantial variation between GP practices in the proportion of consulting women who were offered kits (ranging between 11% and 36%) and the proportion offered kits that returned a self-sample (30%-74%). However, the proportion of eligible women who consulted that returned a sample increased with increasing proportion invited (see Figure 2 correlation coefficient r=0.8, p=0.04). This suggested that the more women that are offered kits would result in more returning a self-sample. 
Similarly, there was considerable variation within GP practices in the offering of self-sampling kits. Some clinicians offered none throughout the study, whereas at three practices a single GP offered more than half of all kits offered at the practice. The majority (74.8%) of kits were offered by a doctor, (rather than a nurse or health care assistant), although again this varied considerably between practices (range 40%-96%).
Based on informal feedback from GP practices the offering of self-sampling kits did not substantially increase consultation time and was generally acceptable to GPs, nurses and health care assistants. 
Discussion
Main findings
Targeted offering of self-sampling to cervical screening non-attenders opportunistically in primary care is feasible and acceptable. The potential impact of this approach on screening coverage may be less than expected given that 11% of women who tested HPV negative came for cytology testing in the next 6 months. However, it may be that the offer of self-sampling acts as a prompt to encourage women to re-engage with the cervical screening programme. 
The proportion of women offered kits varied substantially both between and within GP practices. We were unable to disentangle precise reasons but anecdotally some GPs reported having limited time in consultation (particularly if women had complicated or multiple problems) or that they saw no or very few eligible women (usually due to sub-specialty), some expressed concern that the test was inferior to cervical cytology, that test uptake did not contribute to the annual reward and incentive programme (Quality of Framework, QoF) and some believed that women would eventually come for a smear.  The fact that more samples were returned when more kits were offered indicate that there is scope to further increase uptake and identified the need to motivate individual GPs to participate in this intervention. This taken together with the positive relationship between the proportion of women that returned a sample with the proportion who were invited implies that differences in uptake were largely determined by individual GPs rather than characteristics of the women. 
Offering kits using this targeted approach seemed to be GP-led. A likely explanation is that a high proportion of nurse consultations will be for cervical screening.
Strengths and limitations
As far as we are aware this is the first study to examine targeted offering of self-sampling for HPV testing in primary care. Another key strength of the study is that the design closely resembled current clinical practice, meaning that our findings will be informative for future studies or implementation of the strategy into the screening programme. 
A major limitation of the study was that self-sampling was not included as part of the national screening programme and therefore did not count towards coverage or change the women’s screening status. This was often highlighted as being a disincentive for offering self-sampling because GP payments (QoF) are linked to coverage and because it inferred that self-sampling was inferior to cytology.  A further limitation was that we were unable to calculate the exact number of cervical screening non-attenders over the study period. Also, we relied on cytology data in GP records to identify eligible women but cervical screening status is not always up to date (particularly for women newly registered at the GP practice in the past year). Inviting clinicians were asked to confirm eligibility before offering kits but it is possible that some ineligible women may have been offered kits.  Furthermore, over half (59%) of women in the study had been registered at the GP practice for over one year. The GP practices in our study opted to take part and most were from a single area in London, and therefore may not be representative of the rest of England. Indeed, we purposefully targeted some practices because they had low screening coverage, however, we did not find a relationship between invitation rates and coverage (range 59.5% to 70.6%). 
Interpretation in light of other studies
The proportion of women testing HPV positive who attended follow up within 3 months was similar to that of a previous UK self-sampling study ADDIN EN.CITE (11) (56% vs 59%, respectively). However, by the end of our study this figure was in line with what has been reported in most other studies (81-90%). ADDIN EN.CITE (3, 4, 6, 8, 17) 
Heterogeneity between centres has also been reported in an Italian trial  ADDIN EN.CITE (10). Giorgi Rossi et al suggested that this is driven by underlying logistical and organisational differences. Similarly, in our study the differences in self-sample return rates could relate to whether or not women were encouraged to collect their sample in clinic. Return rates for vaginal self-sampling for chlamydia testing for kits taken home are known to be low.(18) Unfortunately, accurate information on whether or not samples were taken in clinic or at home were not available for our study.
The return rates in our study are not directly comparable to those in the two published UK studies which posted self-sampling kits to cervical screening non-attenders (6% ADDIN EN.CITE (12) and 8% ADDIN EN.CITE (11) returned a self-sample) which were population-based. However, it seems reasonable to conclude we achieved very similar return rates but with much fewer wasted kits.
Implications
Cervical screening in England is set to undergo major changes in the coming years, which are likely to include a switch to primary HPV screening. It seems almost inevitable that some form of self-sampling will also be incorporated for cervical screening non-attenders given the acceptability, ADDIN EN.CITE (19-21) ease of use and advances in test performance. ADDIN EN.CITE (2) Sending self-sampling kits directly to screening non-attenders appears to work well in studies in other countries, but in the UK the optimal approach is likely to be multi-faceted. Targeted offering of self-sampling kits, even in a busy general practice setting seems to be possible. Using this approach could help minimise costs by reducing kit wastage (two-thirds of kits given out were returned). Other factors that need further consideration include the possible impact of introducing self-sampling on screening behaviour of women who currently attend screening regularly  ADDIN EN.CITE (22) and whether there should be a higher threshold for triage for women testing HPV positive on a self-sample.  In the future, the uptake of self-sampling could further increase as HPV testing becomes more widely recognised by the public and primary care givers as an effective test for cervical screening.  
The high diagnostic yield of invasive cancers observed in this study suggests that the women targeted were from a very high risk group and that self-sampling is valuable in non-attenders. There were fewer than expected CIN2/3 lesions identified but this may have been due to small numbers (i.e. a chance finding).






Table 1 Characteristics of participating GP practices and women who returned a self-sample by GP practice	
 	Practice 1	Practice 2	Practice 3	Practice 4	Practice 5	Practice 6	TOTAL
	n (%)	n (%)	n (%)	n (%)	n (%)	n (%)	n (%)
Characteristics of participating GP practices 
List size (EMIS)a at study start	8,070	9,563	12,955	5,913	4,953	8,248	49,702
List size (Toolkit)b in June 2014	8,020	9,426	12,868	5,968	4,979	8,691	49,952
Estimated number of women aged 25-64 in practicec (June 2014)	2,488	2,957	3,355	1,900	1,404	2,355	14,460
Age appropriate cervical screening coverage§ (Toolkit)b (June 2014)	70.90%	75.20%	71.80%	70.20%	60.90%	63.40%	 
Estimated number of women aged 25-64, >6 months overdue cervical screeningc (June 2014)	724	733	946	566	549	862	4,381
Characteristics of women who returned a self-sample
Total number of women who returned a self-sample	122	64	35	26	24	21	292
Age at self-sample							 
25-49 years	100 (82)	53 (82.8)	25 (71.4)	18 (69.2)	20 (83.3)	15 (71.4)	231 (79.1)
50-64 years	22 (18)	11 (17.2)	10 (28.6)	8 (30.8)	4 (16.7)	6 (28.6)	61 (20.9)
Ethnicity							 
White	59 (48.4)	28 (43.8)	19 (54.3)	12 (46.2)	10 (41.7)	12 (57.1)	140 (47.9)
Black	23 (18.9)	9 (14.1)	6 (17.1)	7 (26.9)	8 (33.3)	1 (4.8)	54 (18.5)
Asian	9 (7.4)	20 (31.3)	9 (25.7)	4 (15.4)	1 (4.2)	3 (14.3)	46 (15.8)
Mixed	3 (2.5)	0 (0)	0 (0)	0 (0)	1 (4.2)	0 (0)	4 (1.4)
Other ethnic group 	3 (2.5)	2 (3.1)	1 (2.9)	3 (11.5)	1 (4.2)	1 (4.8)	11 (3.8)
Unknown	25 (20.5)	5 (7.8)	0 (0)	0 (0)	3 (12.5)	4 (19)	37 (12.7)
Screening statuse							 
Late	30 (24.6)	17 (26.6)	6 (17.1)	9 (34.6)	7 (29.2)	6 (28.6)	75 (25.7)
Very late	42 (34.4)	12 (18.8)	10 (28.6)	5 (19.2)	6 (25)	5 (23.8)	80 (27.4)
Never	50 (41)	35 (54.7)	19 (54.3)	12 (46.2)	11 (45.8)	10 (47.6)	137 (46.9)
aData from EMIS GP record system at study start
bData from the NCIN cancer toolkit GP practice profiles (https://www.cancertoolkit.co.uk/Profiles/PracticePublic/Filters). Data in the toolkit were extracted from the Open Exeter system in June 2014, and cover the period 2007/08-2013/14.
cEstimated from toolkit data by multiplying the number of women aged 25-64 attending cervical screening within target period by (1-coverage)
dAge appropriate coverage is the number of women registered at the practice screened adequately in the previous 3.5 years (if aged 24-49) or 5.5 years (if aged 50-64) divided by the number of eligible women on last day of review period




Table 2 Cytology results for women who tested HPV positive on a self-sample
				








aOne CIN1 (confirmed on biopsy), 3 normal on subsequent cytology or colposcopy
bTwo invasive squamous cell carcinoma
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